Onkologie, Hämatologie - Daten und Informationen
SitemapSitemap  


Morbus Hodgkin beim Erwachsenen: Literaturreferenzen des Artikels

Autor/en: B. Klimm, K. Behringer, A. Engert
Letzte Änderung: 16.09.2004
  • Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland, in Zusammenarbeit mit dem Robert-Koch-Institut.
    Krebs in Deutschland, Häufigkeiten und Trends. 4. überarbeitete, aktualisierte Ausgabe.
    Saarbrücken, 2004.


  • Borchmann P, Schnell R, Fuss I, et al.
    Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma.
    Blood 2002;100:3101-3107. PM:12384405
    [Medline]


  • Diehl V, Franklin J, Pfreundschuh M, et al.
    Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease.
    N Engl J Med 2003;348:2386-2395. PM:12802024
    [Medline]


  • Engert A, Schiller P, Josting A, et al.
    Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin’s Lymphoma: Results of the HD8 trial of the German Hodgkin’s Lymphoma Study Group.
    J Clin Oncol 2003;21:3601-3608. PM:12913100
    [Medline]


  • Glossmann JP, Josting A, Pfistner B, et al.
    A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2).
    Ann Hematol 2002;81:424-429. PM:12223998
    [Medline]


  • Harris NL, Jaffe ES, Diebold J, et al.
    The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997.
    Ann Oncol 1999;10:1419-1432. PM:10643532
    [Medline]


  • Hasenclever D, Diehl V.
    A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.
    N Engl J Med 1998;339:1506-1514. PM:9819449
    [Medline]


  • Hodgkin T.
    On some morbid appaerances of the absorbent glands and spleen.
    Medico-Churgical Trans 1832;17:68-97. PM:4630498
    [Medline]


  • Jarrett RF, MacKenzie J.
    Epstein-Barr virus and other candidate viruses in the pathogenesis of Hodgkin's disease.
    Semin Hematol 1999;36:260-269. PM:10462326
    [Medline]


  • Josting A, Franklin J, May M, et al.
    New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002a;20:221-230. PM:11773173
    [Medline]


  • Josting A, Rudolph C, Reiser M, et al.
    Time-intensified Dexamethasone/ cisplatin/ cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
    Ann Oncol 2002b;13:1628-1635. PM:12377653
    [Medline]


  • Josting A, Rueffer U, Franklin J, et al.
    Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group.
    Blood 2000;96:1280-1286. PM:10942369
    [Medline]


  • Kuppers R, Rajewsky K.
    The origin of Hodgkin and Reed/Sternberg cells in Hodgkin’s disease.
    Annu Rev Immunol 1998;16:471-493. PM:9597138
    [Medline]


  • Rehwald U, Schulz H, Reiser M, et al.
    Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group.
    Blood 2003;101:420-424. PM:12509381
    [Medline]


  • Rosenberg SA, Boiron M, DeVita VT Jr, et al.
    Report of the Committee on Hodgkin's Disease Staging Procedures.
    Cancer Res 1971;31:1862-1863. PM:5121695
    [Medline]


  • Santoro A, Bredenfeld H, Devizzi L, et al.
    Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study.
    J Clin Oncol 2000;18:2615-2619. PM:10893294
    [Medline]


  • Schmitz N, Pfistner B, Sextro M, et al.
    Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial.
    Lancet 2002;359:2065-2071. PM:12086759
    [Medline]


  • Schmitz N, Sureda A, Robinson S.
    Allogeneic transplantation of hematopoietic stem cells after nonmyeloablative conditioning for Hodgkin's disease: indications and results.
    Semin Oncol 2004;31:27-32. PM:14970934
    [Medline]


  • Sieber M, Franklin J, Tesch H, et al.
    Two Cycles ABVD Plus Extended Field Radiotherapy Is Superior to Radiotherapy Alone in Early Stage Hodgkin’s Disease: Results of the German Hodgkin’s Lymphoma Study Group (GHSG) Trial HD7.
    Blood 2002;100:341a.


Aktuelle Berichte vom 58th
ASH Annual Meeting 2016,
San Diego, Kalifornien, USA [Mehr]
2016 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch:
mehr 
[Mehr]